| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/22/2023 | -11.01% | DA Davidson | $106 → $94 | Maintains | Neutral |
| 11/04/2022 | 0.35% | DA Davidson | $278 → $106 | Downgrades | Buy → Neutral |
| 08/04/2022 | 163.18% | DA Davidson | $352 → $278 | Maintains | Buy |
| 08/04/2022 | 42.01% | Jefferies | $345 → $150 | Downgrades | Buy → Hold |
| 06/02/2022 | 233.24% | DA Davidson | $341 → $352 | Maintains | Buy |
| 02/24/2022 | 222.82% | DA Davidson | $349 → $341 | Maintains | Buy |
| 11/08/2021 | 230.4% | DA Davidson | $395 → $349 | Maintains | Buy |
| 05/05/2021 | 273.95% | DA Davidson | $302 → $395 | Maintains | Buy |
| 02/26/2021 | 185.9% | DA Davidson | $239 → $302 | Maintains | Buy |
| 01/25/2021 | 150.88% | Jefferies | $205 → $265 | Upgrades | Hold → Buy |
| 01/12/2021 | 126.26% | DA Davidson | $205 → $239 | Maintains | Buy |
| 11/05/2020 | 94.07% | DA Davidson | $180 → $205 | Upgrades | Neutral → Buy |
| 06/25/2020 | 55.26% | B. Riley Securities | → $164 | Initiates Coverage On | → Buy |
| 05/06/2020 | -18.58% | DA Davidson | $83 → $86 | Maintains | Neutral |
| 02/27/2020 | -21.42% | DA Davidson | $74 → $83 | Maintains | Neutral |
| 11/08/2019 | -29.94% | DA Davidson | $250 → $74 | Downgrades | Buy → Neutral |
| 07/25/2019 | 23.07% | Jefferies | → $130 | Initiates Coverage On | → Buy |
| 02/27/2019 | 104.49% | Sidoti & Co. | $211 → $216 | Maintains | Buy |
| 11/08/2018 | — | Sidoti & Co. | Upgrades | Neutral → Buy | |
| 05/24/2018 | 52.42% | DA Davidson | $135 → $161 | Maintains | Buy |
| 04/19/2018 | — | Sidoti & Co. | Downgrades | Buy → Neutral |
What is the target price for Medifast (MED)?
The latest price target for Medifast (NYSE: MED) was reported by DA Davidson on February 22, 2023. The analyst firm set a price target for $94.00 expecting MED to fall to within 12 months (a possible -11.01% downside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Medifast (MED)?
The latest analyst rating for Medifast (NYSE: MED) was provided by DA Davidson, and Medifast maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Medifast (MED)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medifast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medifast was filed on February 22, 2023 so you should expect the next rating to be made available sometime around February 22, 2024.
Is the Analyst Rating Medifast (MED) correct?
While ratings are subjective and will change, the latest Medifast (MED) rating was a maintained with a price target of $106.00 to $94.00. The current price Medifast (MED) is trading at is $105.63, which is out of the analyst's predicted range.